Surfactant replacement therapy : RDS & beyondDr-Hasen Mia
This presentation is about Surfactant, its use in Respiratory Distress Syndrome & some other conditions of surfactant deficiency due to inactivation like meconium aspiration syndrome & others
Surfactant therapy |medical administration of exogenous surfactantNEHA MALIK
Surfactant therapy is the medical administration of exogenous surfactant. Surfactants used in this manner are typically instilled directly into the trachea. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive.
Surfactant replacement therapy : RDS & beyondDr-Hasen Mia
This presentation is about Surfactant, its use in Respiratory Distress Syndrome & some other conditions of surfactant deficiency due to inactivation like meconium aspiration syndrome & others
Surfactant therapy |medical administration of exogenous surfactantNEHA MALIK
Surfactant therapy is the medical administration of exogenous surfactant. Surfactants used in this manner are typically instilled directly into the trachea. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive.
This is a detailed presentation on Non-Invasive Ventilation in Neonates. it includes modes of NIV, Evidence related to CPAP vs NIV, use of NIV/CPAP and detailed description of CPAP and its use, complications associated with NIV and related management
This is a detailed presentation on Non-Invasive Ventilation in Neonates. it includes modes of NIV, Evidence related to CPAP vs NIV, use of NIV/CPAP and detailed description of CPAP and its use, complications associated with NIV and related management
respiratory difficulty commonly in a preterm neonate and is due to deficiency of pulmonary surfactant. It was formerly known as Hyaline Membrane Disease (HMD).
presented by Dr. Taher
Bronchopulmonary dysplasia is a pathologic process leading to signs and symptoms of chronic lung disease that originates in the neonatal period.
Presented by Dr. Tahir
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
2. Flow of the presentation
• Introduction
• Definition of respiratory distress.
•
3. Introduction
• Respiratory distress is one of the most common reasons an
infant is admitted to the NICU.
• 15% of term infants and 29% of late preterm infants
admitted to the NICU develop significant respiratory
morbidity.
• Neonatal RDS is a frequent cause of increased morbidity
and mortality in neonates.
• Understanding the pathophysiology, clinical presentation,
diagnosis, prevention, and management of this condition
is vital to decreasing morbidity and mortality.
4. Definition of Respiratory Distress
Presence of any 2 of the following features:
1. R.R > 60/min
2. Subcostal/intercostal Recessions
3. Expiratory Grunt /Groaning
Signs should be assessed in context of Spo2,
colour, activity of the baby.
5. Incidence of RDS
• Incidence is inversely proportional to gestational age & birth
weight.
Worldwide data:
• <28 WOG – 60 to 80%
• 32-36WOG- 15 TO 30%
Indian data:
58% in <30 wog
32% b/w 30-32 wog
10% b/w 33-34 wog
• 37 WOG- Term – 5%
• 500-750 gm-54% (NICHD Neonatal Research Network,Fanaroff et.al)
• 751-1000gm- 36%
• 1251-1500gm-22%
• 6.8 to 14.1% of preterm live births in India
• 1.2% of all live births (NATIONAL NEONATAL PERINATAL DATA 2013 report)
7.
Neonatal Respiratory Distress
Signs and symptoms
o Tachypnea (RR > 60/min)
o Nasal flaring
o Retraction
o Grunting
o +/- Cyanosis
o +/- Desaturation
o Decreased air entry
9. Physiologic abnormalities
• Surfactant deficiency- increase in alveolar surface
tension.
• Lung compliance decreased to 10-20% of normal
• Atelectasis…areas not ventilated
• Decrease alveolar ventilation
• Reduce lung volume
• Areas not perfused
14. Chest x-ray:findings can be graded according to the severity
Grade 1 (mild cases): the lungs show fine
homogenous ground glass shadowing
Grade 2: widespread air bronchogram become
visible
Grade 3: confluent alveolar shadowing
Grade 4: complete white lung fields with obscuring of
the cardiac shadow
Radiological
15. Grade 1
Grade 1 (mild cases): the lungs show fine homogenous ground
glass shadowing
16. General Management of Respiratory Distress
o Supplemental oxygen or MV, if needed.
o Continuously monitor with pulse oximeter.
o Obtain a chest radiograph.
o Correct metabolic abnormalities
(acidosis,hypoglycemia).
o Obtain a blood culture & begin an antibiotic
coverage (ampicillin + gentamicin)
21. Management
• Lung maturity testing: lecithin/sphingomyelin (L/S) ratio:
(The normal L/S ratio is 2.0 to 2.5 and is significant for
appropriate fetal lung development. An L/S ratio of less
than 2.0 is significant for immature fetal lung
development)
• Tocolytics to inhibit premature labor. (Commonly used
tocolytic medications include β2 agonists, calcium channel
blockers, NSAIDs, and magnesium sulfate).
22. Antenatal corticosteroid therapy:
• They induce surfactant production and accelerate
fetal lung maturation.
• Are indicated in pregnant women 24-34 weeks'
gestation at high risk of preterm delivery within the
next 7 days.
• Optimal benefit begins 24 hrs after initiation of
therapy and lasts seven days.
Antenatal corticosteroid therapy consists of either :
• Betamethasone 12 mg/dose IM for 2 doses, 24 hrs apart,
or
• Dexamethasone 6 mg/dose IM for 4 doses, 12 hrs apart
23. Monitoring Oxygenation and Ventilation
T
arget SpO2
<30 weeks or wt<1.250gm –88 to 92 %
>30 weeks or wt >1.250gm-88 to 95%
ABG Monitoring: Frequent measurements during
acute stage, do ABG after 30 min of changes in
FiO2/ventilator setting Initiate CPAP as early as possible
In infants with mild RDS.
Start MV if respiratory acidosis (PaCO2 >60 mmHg, PaO2
<50 mmHg or SaO2 <90%) with an FiO2 >0.5, or severe
frequent apnea.
Specific management depends on the cause of distress.
24. Assisted Ventilation of the Neonate
The goals of assisted ventilation are to reduce atelectasis
by providing a constant distending positive airway
pressure.
CPAP /Bubble CPAP with selective surfactant
administration:
non-invasive modalities are preferred over invasive ventilation as they decrease
the risk of mortality, and bronchopulmonary dysplasia (BPD) compared to
invasive ventilation with or without surfactant. The goals of treatment
include keeping SpO2 between 90-95%, and PaCO2
between 45-65 mmHg.
25. CPAP
🠶 Indication- In infants with RDS start CPAP as soon as possible.
🠶The most common cause of failed CPAP is???
🠶 Starting pressure 5 to 7 cm H2O, at flow of 5 to 10 L/min, FiO2
titrated to target SpO2.
🠶Use OG tube to decompress swallowed air.
🠶 As the infant improves, start tapering FiO2, when FiO2 requirement
is 0.3 bring CPAP to 5 cm H2O.
🠶 Discontinue CPAP if no distress and FiO2 remains <0.3.
27. Assisted Ventilation of the Neonate
(Cont.)
Non-invasive Respiratory Support:
Nasal Intermittent Positive Pressure Ventilation (NIPPV) appears superior to CPAP alone for
decreasing extubation failure, the need for intubation in preterm infants, but the same in cost and
safety.
High Flow Nasal Canula: Heated humidified high-flow nasal cannulas (HFNC) are also used in some
centers as an alternative to CPAP to provide positive distending pressure ventilation to neonates with
RDS. As seen in a clinical trial by Roberts et al., HFNC was found to be inferior to CPAP.
28. Mechanical Ventilation:
The goals of mechanical ventilation include providing adequate respiratory
support while balancing the risks of barotrauma, volutrauma, and oxygen
toxicity.
neonates who do not respond to CPAP, develop respiratory acidosis (PH < 7.2
and PaCo2 > 60-65 mm of Hg), hypoxemia (PaO2 < 50 mm of Hg or Fio2 > 0.40 on
CPAP), or severe apnea are managed with endotracheal intubation and
mechanical ventilation.
Time-cycled pressure limited ventilation is the preferred initial mode of
ventilation in preterm infants with RDS.
High-frequency oscillatory ventilation (HFOV) and high-frequency jet ventilation
(HFJV) are often used as rescue modalities when requiring high conventional
ventilator support or concerns for pulmonary air leaks.
29. 30
Exogenous Surfactant Therapy
The targeted treatment for surfactant deficiency is
intratracheal surfactant replacement therapy via an
endotracheal tube.
Improvement in compliance, functional residual
capacity, and oxygenation
Reduces incidence of air leaks
Decreases mortality
Surfactant administered within 30 to 60 minutes of the birth of a premature
neonate is found to be beneficial
30. Types of Surfactant
Natural Surfactants: contain appoproteins SP-B & SP-C
o Curosurf (extract of pig lung mince)
o Survanta (extract of cow lung mince)
o Infasurf (extract of calf lung)
Synthetic Surfactants:do not contain proteins
o Exocerf
o ALEC
o Lucinactant (Surfaxin)
31. However, neonates who receive surfactant for established
RDS, have an increased risk of apnea of prematurity.
According to European census guidelines, the surfactant is
administered to immature babies with FiO2 > 0.3, and
mature babies with FiO2 > 0.4. Currently, there are no
clinically significant advantages of using one type over
another when used in similar doses:Beractant: This is a
modified natural surfactant prepared from minced bovine
lungs with the additives
Poractant alfa: This is a modified natural surfactant
derived from minced porcine lung extract
Calfactant: This is a natural surfactant obtained from
lavaging calf lung alveoli and contains 80%
32. death, and need for mechanical ventilation compared to surfactant
administration through endotracheal intubation.[38] Still, further
investigations are required to prefer the LISA technique as the
standard technique of surfactant administration in place of
endotracheal intubation. If the neonates maintain adequate
respiratory drive with FiO2 <0.3, it should be planned to stop
surfactant and switch to CPAP. Oxygen saturation (>90%),
thermoregulation (36.5 to 37.5 C), and fluid and nutrition
status should be monitored.
33. 1. warmth - radiant warmer/ incubator
2. maintain hydration
3. nutrition
b) initially d5w or d10w (with protein, if possible) npo if rr >
60 or moderate/severe 8.
work of breathing
c)gavage feeds if stable, conider parteral feed
if entreal feed is deleyed.
4. antibiotics if at riskfor pneumonia/sepsis
5. supplemental oxygen
6. spo2 monitoring, with appropriate target for infantsat
riskfor rop.
34. Mode of administration of Surfactant
Dosing may be
divided into 2
alliquots and
adminitered via
a 5-Fr catheter
passed in the
ET
37. PROGNOSIS
Prognosis of infants managed with
antenatal steroids, respiratory support,
and exogenous surfactant therapy is
excellent. Mortality is less than 10%,
with some studies showing survival rates
of up to 98% with advanced care.